Compagnie Lombard Odier SCmA Has $54.96 Million Stock Position in Merck & Co., Inc. $MRK

Key Points

• Compagnie Lombard Odier SCmA reduced its stake in Merck & Co., Inc. by 13.8%, bringing its total holdings to approximately $54.96 million in value.
• The recent quarterly earnings report showed Merck posting $2.13 earnings per share, exceeding analysts' expectations of $2.03.
• Merck has declared a quarterly dividend of $0.81 per share, with a current annualized yield of 4.0%.

Compagnie Lombard Odier SCmA cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 13.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 694,309 shares of the company's stock after selling 111,246 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Merck & Co., Inc. were worth $54,962,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Barnes Dennig Private Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. during the first quarter worth approximately $27,000. CBIZ Investment Advisory Services LLC increased its position in shares of Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company's stock valued at $34,000 after purchasing an additional 221 shares during the period. MorganRosel Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the first quarter valued at approximately $36,000. MJT & Associates Financial Advisory Group Inc. bought a new stake in shares of Merck & Co., Inc. during the first quarter valued at approximately $48,000. Finally, Fiduciary Wealth Partners LLC bought a new stake in shares of Merck & Co., Inc. during the first quarter valued at approximately $48,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MRK. Morgan Stanley lowered their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Berenberg Bank cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price target for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Finally, Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of "Hold" and an average target price of $106.41.

Merck & Co., Inc. Stock Down 1.3%

MRK stock opened at $80.44 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average price of $82.72 and a two-hundred day moving average price of $82.24. The company has a market cap of $200.93 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 0.84 and a beta of 0.37. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $118.16.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be given a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend is Monday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 49.92%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.